Cross - Sectional study requiring one visit at the investigators office for the data collection. * Target Group: Patients that suffer from Bipolar Disorder Type 1. * YMRS - HAMILTON and GAF scales are going to be used to assess the clinical outcome. The findings are going to be based on the different scores reported by Specialists (before the patients started to use as a therapy atypical antipsychotics / at the time that the visit actually takes place for the cause of the study.) We predefine the time period that the patient should be using atypical antipsychotics at minimum (2 months). * The first 9 consecutive patients that visit the Specialist and meet the entry criteria and signs the ICF will be recruited in the study.
Study Type
OBSERVATIONAL
Enrollment
540
Research Site
Agrinio, Greece
Research Site
Alexandroupoli, Greece
Research Site
Athens, Greece
Research Site
Crete, Greece
Research Site
Elefsina, Greece
Research Site
Ioannina, Greece
Research Site
Karditsa, Greece
Research Site
Katerini, Greece
Research Site
Kos, Greece
Research Site
Kozani, Greece
...and 10 more locations
Difference in the scores reported in YMRS and Hamilton - D scales from baseline(start of therapy)
Time frame: Assessment of the progress of disease 2 to 4 months after the initiation of the therapy(baseline)
Assessment of functioning - Relative score reported in GAF scale
Time frame: 2 - 4 months after the initiation of the therapy. No baseline comparison
To depict sociodemographic characteristics and comorbidities.
Time frame: Reported at the site visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.